Western pharmaceutical companies need to tap into “mind-bogglingly impressive innovation” in China despite “anti-Chinese sentiment” in US life sciences, according to the chief executive of Genmab, one of Europe’s leading biotech companies.Jan van de Winkel, head of the DKK132bn ($19bn) Danish biotech that recently announced its first acquisition by buying a US-Chinese drugmaker, said that pharma groups cannot ignore Chinese biotechs that “are growing very, very rapidly with the government there investing massive amounts of money”.
歐洲領先生物技術公司之一Genmab的首席執行官表示，盡管美國生命科學領域存在“反華情緒”，但西方制藥公司需要對中國“令人印象深刻到難以置信程度的創新”加以利用。
您已閱讀11%（617字），剩余89%（5128字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。